Abstract
Pseudomonas aeruginosa clinical isolate PA35 is resistant to amino- and ureido-penicillins, has intermediate susceptibility to cefsulodin, cefepime and aztreonam, and is susceptible to imipenem and ceftazidime. Cloning and sequencing revealed a new beta-lactamase variant, OXA-35, sharing 96% amino acid identity with OXA-10. OXA-35 displays a restricted-substrate hydrolysis profile with improved hydrolysis of amoxicillin and cloxacillin compared with OXA-10. OXA-35 differs from derivatives OXA-19 and OXA-28 by one amino acid substitution and may be a progenitor of these OXA-13-like extended-spectrum beta-lactamases.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Amino Acid Substitution / genetics
-
Anti-Bacterial Agents / pharmacology
-
Cloning, Molecular
-
Cloning, Organism
-
DNA Transposable Elements / genetics
-
Drug Resistance, Bacterial / genetics
-
Genes, Bacterial
-
Humans
-
Molecular Sequence Data
-
Pseudomonas aeruginosa / drug effects
-
Pseudomonas aeruginosa / enzymology*
-
Pseudomonas aeruginosa / genetics
-
Pseudomonas aeruginosa / isolation & purification
-
beta-Lactamases / chemistry*
-
beta-Lactamases / genetics
-
beta-Lactams
Substances
-
Anti-Bacterial Agents
-
DNA Transposable Elements
-
beta-Lactams
-
beta-lactamase OXA-10
-
beta-Lactamases